Author:
Booth Christopher M.,Calvert A. Hilary,Giaccone Giuseppe,Lobbezoo Marinus W.,Seymour Lesley K.,Eisenhauer Elizabeth A.
Reference6 articles.
1. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types;Baselga;J Clin Oncol,2002
2. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review;Eskens;Eur J Cancer,2006
3. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice;Parulekar;J Natl Cancer Inst,2004
4. ARIMIDEX: a new oral, once-a-day aromatase inhibitor;Plourde;J Steroid Biochem Mol Biol,1995
5. Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331;Ford;Clin Cancer Res,2002
Cited by
78 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献